IMPROVED RESULTS OF TREATMENT OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA BLOOD Linker, C. A., Levitt, L. J., ODONNELL, M., Ries, C. A., Link, M. P., Forman, S. J., FARBSTEIN, M. J. 1987; 69 (4): 1242-1248

Abstract

We designed a treatment program to improve the outcome for adults with acute lymphoblastic leukemia (ALL). Treatment included a remission-induction phase followed by intensive alternating cycles of non-cross-resistant chemotherapy and prolonged oral maintenance therapy. Eighty-one consecutive previously untreated patients were entered on this study. Ninety-four percent of patients entered complete remission. A Kaplan-Meier analysis predicts that 53% +/- 9% (SEM) of patients in remission will remain free of disease at 3 years. Neither age, sex, WBC count, nor immunophenotype had a significant effect on remission duration. This program of intensive cyclical chemotherapy has improved the disease-free survival of patients with adult ALL.

View details for Web of Science ID A1987G733000041

View details for PubMedID 3470055